Cargando…

Ethnic inequalities in clozapine use among people with treatment-resistant schizophrenia: a retrospective cohort study using data from electronic clinical records

PURPOSE: Clozapine is the most effective intervention for treatment-resistant schizophrenia (TRS). Several studies report ethnic disparities in clozapine treatment. However, few studies restrict analyses to TRS cohorts alone or address confounding by benign ethnic neutropenia. This study investigate...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Freitas, Daniela Fonseca, Patel, India, Kadra-Scalzo, Giouliana, Pritchard, Megan, Shetty, Hitesh, Broadbent, Matthew, Patel, Rashmi, Downs, Johnny, Segev, Aviv, Khondoker, Mizanur, MacCabe, James H., Bhui, Kamaldeep, Hayes, Richard D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246775/ https://www.ncbi.nlm.nih.gov/pubmed/35246709 http://dx.doi.org/10.1007/s00127-022-02257-3

Ejemplares similares

Ethnic inequalities in treatment with clozapine
por: Fonseca De Freitas, D., et al.
Publicado: (2022)

Using a statistical learning approach to identify sociodemographic and clinical predictors of response to clozapine
por: Fonseca de Freitas, Daniela, et al.
Publicado: (2022)

Risk of readmission in patients with schizophrenia and schizoaffective disorder newly prescribed clozapine
por: Kesserwani, Jad, et al.
Publicado: (2019)

Predictors of long-term (≥ 6 months) antipsychotic polypharmacy prescribing in secondary mental healthcare
por: Kadra, Giouliana, et al.
Publicado: (2016)

Defining severity of personality disorder using electronic health records: short report
por: Monk-Cunliffe, Jonathan, et al.
Publicado: (2023)

A predictor model of treatment resistance in schizophrenia using data from electronic health records
por: Kadra-Scalzo, Giouliana, et al.
Publicado: (2022)

Ethnic inequalities in involuntary admission under the Mental Health Act: an exploration of mediation effects of clinical care prior to the first admission
por: Freitas, Daniela Fonseca, et al.
Publicado: (2023)

Clinical correlates of early onset antipsychotic treatment resistance
por: Fonseca de Freitas, Daniela, et al.
Publicado: (2022)

Clozapine and all‐cause mortality in treatment‐resistant schizophrenia: a historical cohort study
por: Cho, J., et al.
Publicado: (2018)

Mental healthcare utilisation by patients before and after receiving paliperidone palmitate treatment: mirror image analyses
por: Kadra-Scalzo, Giouliana, et al.
Publicado: (2022)

Incidence of suicidality in people with depression over a 10-year period treated by a large UK mental health service provider
por: Francis, Emma R., et al.
Publicado: (2021)

COVID-related hospitalization, intensive care treatment, and all-cause mortality in patients with psychosis and treated with clozapine
por: Govind, Risha, et al.
Publicado: (2022)

Antipsychotic polypharmacy prescribing and risk of hospital readmission
por: Kadra, Giouliana, et al.
Publicado: (2017)

The Effect of Clozapine on Premature Mortality: An Assessment of Clinical Monitoring and Other Potential Confounders
por: Hayes, Richard D., et al.
Publicado: (2015)

Extracting antipsychotic polypharmacy data from electronic health records: developing and evaluating a novel process
por: Kadra, Giouliana, et al.
Publicado: (2015)

Identifying mortality risks in patients with opioid use disorder using brief screening assessment: Secondary mental health clinical records analysis
por: Bogdanowicz, Karolina Magda, et al.
Publicado: (2016)

Cohort profile of the South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLaM BRC) Case Register: current status and recent enhancement of an Electronic Mental Health Record-derived data resource
por: Perera, Gayan, et al.
Publicado: (2016)

S221. QUANTITATIVE SYSTEMS PHARMACOLOGY AS AN ALTERNATIVE TO CHLORPROMAZINE EQUIVALENTS: PREDICTIVE VALIDATION FROM A CRIS DATABASE EXPERIMENT
por: Geerts, Hugo, et al.
Publicado: (2018)

Clozapine treatment and risk of COVID-19 infection: retrospective cohort study
por: Govind, Risha, et al.
Publicado: (2021)

Reasons for discontinuing clozapine: A cohort study of patients commencing treatment
por: Legge, Sophie E., et al.
Publicado: (2016)

Clozapine-induced agranulocytosis
por: Mijovic, Aleksandar, et al.
Publicado: (2020)

Impact of the COVID-19 pandemic on remote mental healthcare and prescribing in psychiatry: an electronic health record study
por: Patel, Rashmi, et al.
Publicado: (2021)

Comparing psychotropic medication prescribing in personality disorder between general mental health and psychological services: retrospective cohort study
por: Kadra-Scalzo, Giouliana, et al.
Publicado: (2021)

Predicting parkinsonism side-effects of antipsychotic polypharmacy prescribed in secondary mental healthcare
por: Kadra, Giouliana, et al.
Publicado: (2018)

41. RECONSIDERING THE EVIDENCE FOR CLOZAPINE FOR TREATMENT REFRACTORY SCHIZOPHRENIA
por: MacCabe, James
Publicado: (2018)

Clozapine-induced myocarditis: electronic health register analysis of incidence, timing, clinical markers and diagnostic accuracy
por: Segev, Aviv, et al.
Publicado: (2021)

Adverse outcomes associated with recorded victimization in mental health electronic records during the first UK COVID-19 lockdown
por: Kadra-Scalzo, Giouliana, et al.
Publicado: (2022)

Correlates of late-onset antipsychotic treatment resistance
por: Fonseca De Freitas, D., et al.
Publicado: (2022)

Clozapine-induced myocarditis: electronic health register analysis of incidence, timing, clinical markers and diagnostic accuracy – ERRATUM
por: Segev, Aviv, et al.
Publicado: (2021)

The association between neighbourhood characteristics and physical victimisation in men and women with mental disorders
por: Bhavsar, Vishal, et al.
Publicado: (2020)

Negative Symptoms in Early-Onset Psychosis and Their Association With Antipsychotic Treatment Failure
por: Downs, Johnny, et al.
Publicado: (2019)

The lived experience of clozapine discontinuation in patients and carers following suspected clozapine-induced neutropenia
por: Oloyede, Ebenezer, et al.
Publicado: (2023)

Inpatient use and area-level socio-environmental factors in people with psychosis
por: Heslin, Margaret, et al.
Publicado: (2018)

Long‐term antipsychotic polypharmacy prescribing in secondary mental health care and the risk of mortality
por: Kadra, G., et al.
Publicado: (2018)

41.3 COULD CLOZAPINE REDUCE VIOLENT OFFENDING?
por: Bhavsar, Vishal, et al.
Publicado: (2018)

Management of clozapine treatment during the COVID-19 pandemic
por: Gee, Siobhan, et al.
Publicado: (2020)

Predicting high-cost care in a mental health setting
por: Colling, Craig, et al.
Publicado: (2020)

Clozapine Response in Schizophrenia and Hematological Changes
por: Blackman, Graham, et al.
Publicado: (2021)

Distinctive pattern of neutrophil count change in clozapine-associated, life-threatening agranulocytosis
por: Taylor, David, et al.
Publicado: (2022)

Establishing the characteristics of an effective pharmacogenetic test for clozapine-induced agranulocytosis
por: Verbelen, M, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_j2vnt998b36bdjjk46o5o09k65